Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06343402 | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | recruiting | Phase 1 | 350 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 5 | Sep 3, 2026 | clinicaltrials |
| NCT06405230 | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 2 | GlaxoSmithKlineINDUSTRY |
| 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | recruiting | Phase 1 / Phase 2 | 160 | TRIANA Biomedicines, Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06049212 | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)(TroFuse-008) | active not recruiting | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT07027514 | A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 | 60 | Ankyra Therapeutics, IncINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07180862 | A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants | active not recruiting | Phase 1 | 160 | Bio-Thera SolutionsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03401385 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | active not recruiting | Phase 1 | 890 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07355231 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI(GuidedRT) | not yet recruiting | Phase 1 / Phase 2 | 10 | Xemed LLCINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT05013450 | Dupilumab_Metastatic NSCLC | active not recruiting | Phase 1 / Phase 2 | 33 | Thomas MarronOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06461156 | A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | recruiting | Phase 1 | 230 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07070440 | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | recruiting | Phase 1 / Phase 2 | 180 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07079475 | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | recruiting | Phase 1 / Phase 2 | 220 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | active not recruiting | Phase 1 | 498 | Genentech, Inc.INDUSTRY | 17 | Aug 28, 2026 | clinicaltrials |
| NCT05777603 | Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05949606 | A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06475937 | A Study of DM001 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 128 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT06813365 | Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) | recruiting | Phase 1 | 300 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07117214 | A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers | recruiting | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07660055 | Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors | recruiting | Phase 1 | 156 | Novartis PharmaceuticalsINDUSTRY | 4 | Aug 27, 2026 | clinicaltrials |
| NCT06863233 | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | recruiting | Phase 1 / Phase 2 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 25, 2026 | clinicaltrials |
| NCT07784959 | Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | recruiting | Phase 1 | 54 | Nuvectis Pharma, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04073745 | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT06622174 | Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer(PROMISE) | recruiting | Phase 1 | 32 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | active not recruiting | Phase 1 | 554 | Boehringer IngelheimINDUSTRY | 18 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04505267 | NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials